Fu Yu narrows loss to $1.2m in FY2024

Revenue from continuing operations increased 10.5% year-on-year.

Fu Yu narrowed its net loss to $1.2m during the financial year 2024, improving from the $7.6m loss seen in the previous year.

The company linked this to the increased revenue and operating profits.

Revenue from continuing operations during the period increased 10.5% year-on-year to $114.9m, driven by higher sales in the medical and consumer segments.

Meanwhile, gross profit rose 27.5% to $15.5m with an improved profit margin of 13.5%.

The company’s earnings before interests, taxes, depreciation and amortisation also rose to $8.5m from $600,000 in FY 2023.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia